LCTX.AMEXLineage Cell Therapeutics, INC

Form 4: Lineage Cell Therapeutics CEO Reports Stock Transactions

Sentiment:

SEC Form 4 Filing

📋All filings for Lineage Cell Therapeutics, INC
🔒Login to Follow

Brian M. Culley, President and CEO of Lineage Cell Therapeutics, reports the vesting of restricted stock units and subsequent share withholding for tax obligations.

Summary

  • On February 11, 2025, Brian M. Culley, the President and CEO of Lineage Cell Therapeutics, had 31,249 restricted stock units (RSUs) vest, converting into common shares.
  • The company withheld 12,547 shares at a price of $0.65 to cover statutory tax obligations related to the RSU vesting.
  • Culley now directly owns 213,544 common shares after the reported transactions.
  • These transactions are related to RSUs granted on February 11, 2022, which vest in four equal installments annually.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It reflects part of the executive compensation package.

Stakeholder Impact

  • The vesting of RSUs and subsequent tax withholding may have a minor dilutive effect on existing shareholders.

Key Dates

DateDescription
February 11, 2022Date of grant for 124,997 RSUs, vesting over four years.
February 11, 2023First vesting date for approximately 25% of the RSUs granted on February 11, 2022.
February 11, 2024Second vesting date for approximately 25% of the RSUs granted on February 11, 2022.
February 11, 2025Third vesting date for 31,249 RSUs and subsequent withholding of shares for tax obligations.
February 11, 2026Final vesting date for approximately 25% of the RSUs granted on February 11, 2022.
February 12, 2025Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.